Indaptus Therapeutics (NASDAQ:INDP) Posts Quarterly Earnings Results, Beats Estimates By $1.55 EPS

Indaptus Therapeutics (NASDAQ:INDP) posted its quarterly earnings data on Thursday. The company reported ($0.02) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.57) by $1.55, Zacks reports.

Indaptus Therapeutics Price Performance

Shares of NASDAQ INDP traded up $0.01 during mid-day trading on Friday, reaching $1.07. The company’s stock had a trading volume of 130,848 shares, compared to its average volume of 114,071. The firm has a market capitalization of $121.17 million, a PE ratio of -0.17 and a beta of 1.18. The stock has a fifty day moving average of $2.51 and a two-hundred day moving average of $2.21. Indaptus Therapeutics has a 52 week low of $0.92 and a 52 week high of $8.57.

Institutional Trading of Indaptus Therapeutics

A hedge fund recently bought a new position in Indaptus Therapeutics stock. Virtu Financial LLC purchased a new position in Indaptus Therapeutics, Inc. (NASDAQ:INDP) in the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 18,997 shares of the company’s stock, valued at approximately $55,000. Virtu Financial LLC owned 1.72% of Indaptus Therapeutics at the end of the most recent reporting period. Institutional investors own 7.06% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. Wall Street Zen upgraded shares of Indaptus Therapeutics to a “hold” rating in a research note on Saturday, June 27th. Weiss Ratings reissued a “sell (e+)” rating on shares of Indaptus Therapeutics in a research note on Friday, July 17th. One investment analyst has rated the stock with a Sell rating, According to data from MarketBeat, the stock has an average rating of “Sell”.

About Indaptus Therapeutics

Indaptus Therapeutics, Inc, is a clinical-stage biotechnology company focused on developing novel cell- and exosome-based immunotherapies for oncology and infectious diseases. Utilizing its proprietary Natural Killer (NK) Cell Platform, Indaptus engineers allogeneic NK cells with enhanced cytotoxicity and targeted tumor recognition. The company’s Exo-NK Therapeutics program further leverages NK cell–derived exosomes to deliver bioactive molecules and amplify immune responses against disease.

Indaptus’ pipeline includes multiple preclinical candidates that integrate chimeric antigen receptor (CAR) technology with NK cells and exosomes to address hematologic malignancies and solid tumors.